Publication: OncologyTube
Michelina Cairo, M.D., medical oncologist at Texas Oncology–Houston Memorial City discusses the results of the randomized phase III DESTINY-Breast03 study and it's possible impact on HER2-positive breast cancer patients. This research was presented at the 2021 European Society of Medical Oncology (ESMO) Congress.
View the full story at OncologyTube or listen to the OncologyTube Podcast.